Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 42Neoplasms 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 14Ovarian Neoplasms 11Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Lung Neoplasms 6Melanoma 5Fallopian Tube Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Peritoneal Neoplasms 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Carcinoma, Pancreatic Ductal 4Adenocarcinoma 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Lymphoma 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lymphoma, B-Cell 2

Interventions

Fluorouracil 4Paclitaxel 3Leucovorin 3Irinotecan 3napabucasin 2entinostat 2Gemcitabine 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2spartalizumab 1ribociclib 1pembrolizumab 1palbociclib 1olaparib 1irinotecan sucrosofate 1huachansu 1guadecitabine 1fludarabine 1ficlatuzumab 1dostarlimab 1Taxes 1Stem Cell Transplantation 1Sorafenib 1Sirolimus 1Ramucirumab 1Oxaliplatin 1Nivolumab 1Melphalan 1Lutetium-177 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Digestive System Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT02231723 2023-11-18

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
139 enrolled
Gastrointestinal

Pancreatic cancer, adult, Digestive System Neoplasms, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Pancreatic Ductal

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡